Sanofi Can Blame Itself for FDA Rejection of Acomplia Weight Drug

Steven T. Gold submits: Rimonabant/Acomplia by Sanofi-Aventis was touted as a blockbuster drug in the obviously lucrative market sector of obesity. Diet and exercise have generally been shown to fail and dieting may actually make obesity more difficult to reverse.
From: biz.yahoo.com